Αρχική World News ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and Melanoma

ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and Melanoma

In the annual Research Round Up podcast series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field presented at the ASCO20 Virtual Scientific Program?” In this episode, 2 editors discuss a range of research presented in head and neck cancer and melanoma.

Listen below, and subscribe to Cancer.Net Podcasts on Apple Podcasts or Google Play for new episodes in this series throughout the summer.

Dr. Ezra Cohen, the 2020 Cancer.Net Associate Editor for Head and Neck Cancer, discusses several studies exploring different treatment options for head and neck cancer. The first is a comparison between 2 different treatment regimens for a combination of chemotherapy and radiation therapy after surgery. [2:43] Next, he discusses 2 studies that looked at different types of targeted therapy. The first of these explored a drug called axitinib (Inlyta) for the treatment of adenoid cystic carcinoma, which is a type of cancer that often begins in the head and neck. [4:13] The next was an early study of a drug called tipifarnib that targets mutations in the HRAS gene for several cancers, including head and neck squamous cell carcinoma. [5:42] Finally, he discusses 3 studies that explored new immunotherapy treatment combinations for head and neck cancer. [6:34]

Dr. Ryan Sullivan, the 2020 Cancer.Net Associate Editor for Melanoma, discusses several studies across the field of melanoma. First, he discusses a study called OpACIN-neo that looked at the effect of providing a combination of the drugs ipilimumab (Yervoy) and nivolumab (Opdivo) before surgery, called neoadjuvant therapy. [10:58] Next, he discusses the follow-up data from 2 studies that looked at the effects of giving treatment after surgery, called adjuvant therapy. The first is the study KEYNOTE-054, which looked at the immunotherapy drug pembrolizumab (Keytruda) [13:51], and the second is a study called COMBI-d, which looked at the combination of 2 targeted therapies, dabrafenib (Tafinlar) and trametinib (Mekinist). [15:07]

Next, he discusses several studies that explored whether it is better to give patients with advanced melanoma ipilimumab alone or if it is better to combine it with immunotherapy that blocks the PD-1 protein. [16:31] Finally, he discusses a study of a type of therapy that is created using a patient’s own T cells. [21:20]

Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked to in the paragraphs above.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Making the most of your ‘eureka’ moment: getting from the science to the clinic

How can we make the vital journey from research to clinical impact more efficient? It all comes down to empowering researchers to develop an...

Black Women Have Nearly Three Times the Risk of Developing Triple Negative Breast Cancer, Study Says

Triple-negative breast cancer is notoriously hard to treat and tends to be more aggressive. It’s also more common among Black women. A new study...

Pioneer in Autism Diagnosis And Treatment Dies At 97

The community is mourning the loss of a true pioneer in autism diagnosis and treatment who strongly advocated for education for people with autism. Dr....

A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and Acceptable Tolerability in Advanced RCC

In the COSMIC-021 study, cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed...

A celebration of peer review

Peer review is an incredibly important part of how we maintain the excellence of the research we fund. As part of Peer Review Week,...

People with Intellectual Disability at Increased Risk of Cancer

People with intellectual disability are at an increased risk of any cancer, as well as several specific cancer types. The findings from a population-based...